QR kód

Estimating clinical and economic impacts and cost-effectiveness of introducing 20-valent pneumococcal conjugate vaccine in Taiwan’s pediatric National Immunization Program and impacts of a delayed implementation

Following 13-valent pneumococcal conjugate vaccine (PCV13) introduction in Taiwan, pneumococcal disease incidence declined; however, incidences driven by non-PCV13 serotypes highlight the need for broader serotype coverage. In response to recent approval of 20-valent PCV (PCV20) for Taiwanese childr...

Celý popis

Uloženo v:
Hlavní autoři: Ya-Min Yang, Yi-Wei Wang, An Ta, Elizabeth Vinand, Megan Rutherford, Liping Huang
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis Group 2026-12-01
Edice:Human Vaccines & Immunotherapeutics
Témata:
Pneumococcal disease
Taiwan
cost-effectiveness analysis
20-valent pneumococcal conjugate vaccine
15-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
On-line přístup:https://www.tandfonline.com/doi/10.1080/21645515.2026.2694843
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky